Recent news on Fentanyl Transdermal System

Mylan Reports Fourth Quarter & Fiscal 2007 Adjusted Diluted EPS of ...  -  25 May 2007
PR Newswire (press release),Additionally, Mylan's fentanyl transdermal system continues to be the only AB- rated generic alternative on the market and accounted for over 14% of fourth

Mylan Labs Raises 2007 Forecast  -  Apr 10, 2007
International Business Times,It also noted that it benefited from no additional competition for its fentanyl transdermal system, a generic version of Johnson & Johnson’s Duragesic

Mylan Announces Final FDA Approval for Its 12 mcg/hr Fentanyl ...  -  Feb 1, 2007
PipelineReview.com (press release),Mylan's Fentanyl Transdermal System was the first generic class 2 narcotic transdermal product approved by the FDA, and Mylan is now the first generic

FDA OKs Mylan's generic Duragesic  -  Jan 31, 2007
United Press InternationalThe FDA approved Mylan's 12 mcg/hr strength of the fentanyl transdermal system. Mylan, which said it will start shipping the product immediately,

Mylan Gets FDA OK for New Duragesic Dose  -  Jan 31, 2007
Houston Chronicle,The FDA approved Mylan's 12 microgram per hour fentanyl transdermal system, a generic version of the Duragesic pain patch sold by J&J unit Ortho-McNeil.

Mylan Reports Record Quarterly and Nine-Month Revenues, Net Income ...  -  Feb 2, 2007
Drug Newswire (press release),Mylan's fentanyl transdermal system continues to be the only AB-rated generic alternative on the market and accounted for over 15% of third quarter net

Business Briefs: 2/1/07  -  Jan 31, 2007
Pittsburgh Post Gazette,Mylan Laboratories said yesterday that the Food and Drug Administration approved the fifth strength of the fentanyl transdermal system, a pain patch that is

(PRN) - Info Security Products Guide Recognizes IPLocks as Hot ...  -  Jan 31, 2007
Bolsamania.com,...(PRN) - Mylan Announces Final FDA Approval for Its 12 mcg/hr Fentanyl Transdermal System ... [+]. (PRN) - Verizon Supports Hundreds of New York Nonprofit

Mylan Laboratories' Prescription: Fool by Numbers  Nov 2, 2006
...year-ago quarter. Mylan's fentanyl transdermal system was the key growth driver, contributing 20% to total revenues. Net profit ... -Motley Fool Mylan Reports Second Quarter Fiscal 2007 Adjusted Diluted EPS of ...  Nov 1, 2006
Mylan's fentanyl transdermal system accounted for approximately 20% of net revenues and continued to be a key growth driver for net revenues and gross profit ... -PR Newswire (press release), DAVA Announces Exclusive Long-Term Partnership to Market and ...  Aug 15, 2006
...announced today that it will be the exclusive marketer and distributor of Lavipharm Laboratories’ Fentanyl transdermal system in the United States. ... -PharmaLive.com

Mylan No Longer Anticipates Additional Generic Transdermal ...  Aug 7, 2006
Mylan's Fentanyl Transdermal System is the only FDA approved, AB-rated generic alternative to Ortho-McNeil's Duragesic(R) patch. ... -PharmaLive.com

FDA Approval to Lavipharm's Fentanyl Patch  Aug 9, 2006
Lavipharm SA announces the approval to market its generic fentanyl transdermal system from the FDA (Food and Drug Administration), the US healthcare regulator. ... -PipelineReview.com

No more skin patches for 2007, but Mylan EPS in place  Aug 7, 2006
Mylan said its fentanyl transdermal system, which has been cleared by the FDA, is currently the only generic alternative to Ortho-McNeil's Duragesic patch for ... -Pittsburgh Business Times

Mylan Reaffirms Fiscal 2007 Adjusted EPS Guidance of $1.35 - $1.55  Aug 7, 2006
The company raised the EPS guidance by approximately 12.5% on July 26 fully anticipating additional competition for its fentanyl transdermal system. ... -Yahoo! News

Risk of Overdose Deaths Linked to Fentanyl Pain Patch Under ...  Feb 15, 2006
On January 28, 2005, the US FDA granted final approval for Mylan Laboratories, Inc. to market a generic fentanyl transdermal system. ... - Open PR,

Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25  Feb 2, 2006
...revenues of $47.9 million during the third quarter, substantially all of which was due to the Company's launch of its fentanyl transdermal system in January ... - MSN Money

Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25  Feb 2, 2006
...revenues of $47.9 million during the third quarter, substantially all of which was due to the Company's launch of its fentanyl transdermal system in January ... - MSN Money

Overdose Deaths Linked to Fentanyl Pain Patch Being Investigated ...  Feb 1, 2006
...final approval for Mylan Laboratories, Inc. to market a generic fentanyl transdermal system. The manufacturer of Duragesic® has ... - Open PR

Profits up, but sales down at J&J in 4Q  Jan 25, 2006
...with US sales were dented by more than 10%, as generic competition hit a number of products, including Duragesic (fentanyl transdermal system) for chronic pain ... - Pharma Times (subscription)

Johnson & Johnson: Fourth Quarter and Year End 2005 Financial ...  Jan 24, 2006
Sales results for DURAGESIC® (fentanyl transdermal system), a transdermal patch for chronic pain; ULTRACET® (acetaminophen/tramadol hydrochloride), an ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional